Navigation Links
Sodium transporter appears likely target for treating salt-sensitive hypertension
Date:2/26/2013

AUGUSTA, Ga. Genetics and demographics likely put you at risk for salt-sensitive hypertension, and scientists are looking for a way to protect you.

The concept is that free radicals in the kidney prompt the organ to hold onto sodium rather than eliminate excess through urination. Excess sodium, in turn, increases free radical production, said Dr. Paul O'Connor, hypertension researcher in the Section of Experimental Medicine at the Medical College of Georgia at Georgia Regents University.

Blocking the hydrogen transporter HVI best known for its role in helping immune cells produce large amounts of free radicals to kill bacteria may stop the unhealthy, vicious cycle.

"We think HVI overexpression in the kidney fuels the production of too many free radicals, which can activate the sodium transporters to hold onto more sodium, leading to hypertension and kidney damage," O'Connor said.

With the help of a New Investigator Award from the American Heart Association and a HV1 mutant rat, he plans to find out.

Sodium helps the kidneys regulate fluid volume and blood pressure. However being older, black and obese are risk factors for holding onto too much sodium. Nearly 40 percent of blacks and 30 percent of whites with healthy blood pressure have a tendency to hold onto salt and so-called salt sensitivity occurs in nearly 75 percent of blacks and more than half of whites with hypertension.

O'Connor has found HVI in the nephrons of the kidneys where decisions are made about how much sodium to retain. And, when looking at sodium transport inside renal tubule cells, he found a drug he was using inhibited free radical production and started putting the pieces together.

O'Connor and his collaborators developed the HV1 mutant of the Dahl salt-sensitive rat, which becomes hypertensive on a high-salt diet, to test the emerging hypothesis.

"We think if HV1 is not present, you will have reduced salt sensitivity, reduced oxidative stress and reduced renal injury when you feed these animals a high-salt diet," O'Connor said.

If he's correct, targeted treatment for salt-sensitive hypertension may emerge. "We think it might be an interesting target to help inhibit oxidative-stress related cardiovascular disease," O'Connor said.

Although free radicals are a known contributor to cardiovascular disease, antioxidants haven't proven effective therapy, said O'Connor, who would like to directly inhibit the source of free radicals rather than scavenge for them once they are formed. An estimated 1-in-50 patients in the United States develop treatment-resistant hypertension, which increases the risk of heart attack, stroke and other complications, according to studies published in the American Heart Association journal Circulation.

HV1 was discovered in 2006 in immune cells where is helps ensure the proper activity of the enzyme NADPH oxidase, which actually produces free radicals. It's now been found in a variety of cell types, and scientists are exploring its potential role in maladies such as ischemic stroke and cancer. O'Connor notes that his HIV mutant rats do not appear to have a compromised immune system.

O'Connor joined the MCG faculty in 2011.


'/>"/>

Contact: Toni Baker
tbaker@gru.edu
706-721-4421
Medical College of Georgia at Georgia Regents University
Source:Eurekalert  

Related biology news :

1. Common genetic mutation increases sodium retention, blood pressure
2. Southwest regional warming likely cause of pinyon pine cone decline, says CU study
3. Study: Viral reactivation a likely link between stress and heart disease
4. Scientists find gene interactions that make cocaine abuse death 8 times more likely
5. Men more likely to commit research misconduct than female counterparts
6. Host cholesterol secretion likely to influence gut microbiota
7. Climate warming unlikely to cause near-term extinction of Amazon trees, but threats remain
8. Warming climate unlikely to cause extinction of ancient Amazon trees, study finds
9. Researchers identify proteins that indicate which kidney tumors are most likely to spread
10. Rhode Island Hospital: Adult entertainment workers likely to benefit from health care intervention
11. International team discovers likely basis of birth defect causing premature skull closure in infants
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sodium transporter appears likely target for treating salt-sensitive hypertension
(Date:1/4/2017)... Jan. 4, 2017  For the thousands of attendees at this year,s ... in connected health and biometric measurement devices and services, will be featuring ... On display in A&D Medical,s special CES Exhibit Suite , the ... expansion of the company,s WellnessConnected product platform.  ... ...
(Date:12/20/2016)... -- The rising popularity of mobility services such ... significant interest in keyless access systems. Following the ... (BLE), biometrics and near-field communication (NFC) are poised ... technologies in the automotive industry. This evolution from ... opens the market to specialist companies such as ...
(Date:12/16/2016)... 16, 2016 The global wearable medical device market, in ... 2021 from USD 5.31 billion in 2016, at a CAGR of ... ... technological advancements in medical devices, launch of a growing number of ... connectivity among healthcare providers, and increasing focus on physical fitness. ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... Jose, CA (PRWEB) , ... January 17, 2017 , ... ... cultivate a balanced, peaceful and healthy lifestyle, announced today the official launch of its ... and frees the mind. , In development for over a year, the ...
(Date:1/17/2017)... ... January 17, 2017 , ... NeoTrident, a leading provider ... and performance management systems for high-consequence industries, announced today that they have entered ... sciences industry, organizations must pay much more attention to the quality of products ...
(Date:1/17/2017)... , Jan. 17, 2017  Protagonist Therapeutics, ... that it has initiated a global Phase 2b ... oral peptide that targets alpha4beta7 integrin. The aim ... is to evaluate the safety/tolerability and efficacy of ... with moderate to severe active disease. ...
(Date:1/16/2017)... ... January 16, 2017 , ... Appellate ... its decision on the appeal filed by India-based Dishman Pharmaceutical & Chemical Ltd. ... against DPCL and one of its Dishman Group’s 100% wholly owned New Jersey-based ...
Breaking Biology Technology: